NanoZymeX Raises €160K To Develop Lipid Nanoparticle Enzyme Therapies For Rare Diseases

Spun out of University of Basel research, the technology aims to improve treatments for rare genetic disorders such as Pompe disease, enhancing therapeutic activity in affected tissues.

Traditional enzyme replacement therapies often face limited effectiveness due to poor delivery into diseased tissues, inefficient cellular uptake, and immune responses that reduce long-term treatment efficacy.

NanoZymeX is developing a lipid nanoparticle platform that delivers therapeutic enzymes directly into target cells and lysosomes.

Read Also - Stateful Robotics Raises $4.8M To Enhance Long-Term Robot Intelligence

This enhances intracellular delivery reduces immune reactions, and increases enzyme activity where it is most needed. Early preclinical studies show strong delivery efficiency and improved enzyme function in key tissues.

The technology targets lysosomal storage disorders, a group of rare diseases representing a multibillion-dollar market and is designed to boost the performance of existing enzyme therapies.

The platform is adaptable to multiple rare diseases beyond Pompe. NanoZymeX plans to collaborate with pharmaceutical and biotech companies to bring next-generation enzyme therapies to patients.

The funding will help NanoZymeX further develop its lipid nanoparticle technology, conduct additional preclinical studies and prepare for scalable manufacturing. This will support future fundraising and the transition toward clinical trials.

“The support from Venture Kick comes at a critical moment when scientific discoveries need to transition into real companies,” highlighted Boris Sevarika, co-founder of NanoZymeX.

“This type of early funding provides the flexibility needed for company building, business development, and preparing the next stages of financing. It fills a crucial gap between academic research and venture-backed biotech development.”

About NanoZymeX

NanoZymeX develops next-generation enzyme replacement therapies for lysosomal storage diseases. Using advanced delivery technologies, the platform enhances treatment efficacy, reduces immune-related side effects and overcomes limitations of current therapies, offering patients more durable, effective and better-tolerated solutions for enzyme deficiency disorders.